ArticleAmerican journal of cancer research2025

STK405759 targets microtubules, modulates STAT1, and enhances ruxolitinib efficacy in myeloproliferative neoplasms.

Gabriela Rozic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.